2023 was a tricky year for the biopharma field, with many companies downsizing and restructuring their workforces to remain afloat. There are actually indications of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences marketplace during the latter Element of 2023 and possess continued their https://sites.google.com/view/bio-sites/blog